Nukkleus Historical Balance Sheet

NUKK Stock

USD 1.80 0.09 5.26%

Trend analysis of Nukkleus balance sheet accounts such as Total Stockholder Equity of 13.2 M provides information on Nukkleus' total assets, liabilities, and equity, which is the actual value of Nukkleus to its prevalent stockholders. By breaking down trends over time using Nukkleus balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Nukkleus latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Nukkleus is a good buy for the upcoming year.

Nukkleus Inventory

1.91 Million

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nukkleus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Nukkleus Stock please use our How to buy in Nukkleus Stock guide.

About Nukkleus Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Nukkleus at a specified time, usually calculated after every quarter, six months, or one year. Nukkleus Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Nukkleus and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Nukkleus currently owns. An asset can also be divided into two categories, current and non-current.

Nukkleus Balance Sheet Chart

At this time, Nukkleus' Accounts Payable is quite stable compared to the past year. Cash is expected to rise to about 439.6 K this year, although the value of Common Stock will most likely fall to about 23.9 K.

Other Current Liab Total Current Liabilities Common Stock Shares Outstanding Other Stockholder Equity

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on Nukkleus balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Nukkleus are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most accounts from Nukkleus' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Nukkleus current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nukkleus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Nukkleus Stock please use our How to buy in Nukkleus Stock guide.At this time, Nukkleus' Accounts Payable is quite stable compared to the past year. Cash is expected to rise to about 439.6 K this year, although the value of Common Stock will most likely fall to about 23.9 K.

	2021	2023	2024 (projected)
Total Current Liabilities	7.5M	8.6M	9.0M
Other Current Liabilities	2.5M	4.1M	4.3M

Total Current Liabilities Other Current Liab

Nukkleus balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Long Term Debt	Net Receivables	Non Current Liabilities Total	Other Current Assets	Short Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock	Current Deferred Revenue
Total Assets		0.81	0.95	0.98	0.93	-0.91	0.98	0.94	0.91	-0.28	0.86	0.95	0.9	0.74	0.75	0.05	0.39	-0.08	0.88	0.92	0.99	-0.92	0.93	0.84
Other Current Liab	0.81		0.89	0.73	0.64	-0.65	0.74	0.76	0.76	-0.44	0.7	0.88	0.93	0.72	0.35	0.06	0.83	-0.02	0.93	0.58	0.74	-0.82	0.69	0.55
Total Current Liabilities	0.95	0.89		0.88	0.89	-0.92	0.89	0.89	0.88	-0.41	0.81	1.0	0.97	0.76	0.73	0.04	0.51	-0.08	0.95	0.86	0.89	-0.96	0.86	0.84
Total Stockholder Equity	0.98	0.73	0.88		0.9	-0.87	0.99	0.93	0.89	-0.2	0.85	0.87	0.82	0.68	0.73	0.0	0.31	-0.13	0.79	0.91	1.0	-0.86	0.92	0.8
Net Debt	0.93	0.64	0.89	0.9		-0.95	0.89	0.84	0.81	-0.29	0.82	0.91	0.83	0.73	0.89	0.18	0.15	0.06	0.81	0.97	0.9	-0.87	0.87	0.91
Retained Earnings	-0.91	-0.65	-0.92	-0.87	-0.95		-0.87	-0.85	-0.84	0.28	-0.76	-0.92	-0.82	-0.71	-0.9	-0.03	-0.15	0.1	-0.8	-0.94	-0.87	0.94	-0.89	-0.96
Accounts Payable	0.98	0.74	0.89	0.99	0.89	-0.87		0.92	0.88	-0.22	0.84	0.87	0.82	0.65	0.74	-0.04	0.32	-0.17	0.79	0.91	0.99	-0.86	0.92	0.81
Cash	0.94	0.76	0.89	0.93	0.84	-0.85	0.92		0.97	-0.2	0.81	0.88	0.83	0.75	0.68	0.02	0.35	-0.1	0.79	0.83	0.93	-0.89	0.87	0.78
Cash And Short Term Investments	0.91	0.76	0.88	0.89	0.81	-0.84	0.88	0.97		-0.16	0.79	0.87	0.79	0.78	0.63	0.02	0.31	-0.11	0.75	0.78	0.9	-0.92	0.85	0.76
Common Stock Shares Outstanding	-0.28	-0.44	-0.41	-0.2	-0.29	0.28	-0.22	-0.2	-0.16		-0.61	-0.39	-0.4	-0.03	-0.36	0.18	-0.42	0.09	-0.42	-0.33	-0.2	0.28	-0.2	-0.29
Other Stockholder Equity	0.86	0.7	0.81	0.85	0.82	-0.76	0.84	0.81	0.79	-0.61		0.8	0.74	0.57	0.7	0.03	0.34	0.0	0.72	0.83	0.85	-0.74	0.77	0.71
Total Liab	0.95	0.88	1.0	0.87	0.91	-0.92	0.87	0.88	0.87	-0.39	0.8		0.97	0.79	0.72	0.14	0.5	0.01	0.96	0.86	0.88	-0.96	0.86	0.84
Total Current Assets	0.9	0.93	0.97	0.82	0.83	-0.82	0.82	0.83	0.79	-0.4	0.74	0.97		0.77	0.6	0.2	0.65	0.08	1.0	0.77	0.82	-0.89	0.79	0.74
Common Stock	0.74	0.72	0.76	0.68	0.73	-0.71	0.65	0.75	0.78	-0.03	0.57	0.79	0.77		0.42	0.39	0.39	0.3	0.75	0.58	0.7	-0.8	0.77	0.68
Net Tangible Assets	0.75	0.35	0.73	0.73	0.89	-0.9	0.74	0.68	0.63	-0.36	0.7	0.72	0.6	0.42		-0.02	-0.14	-0.12	0.59	0.94	0.73	-0.71	0.74	0.9
Long Term Debt	0.05	0.06	0.04	0.0	0.18	-0.03	-0.04	0.02	0.02	0.18	0.03	0.14	0.2	0.39	-0.02		0.0	0.98	0.2	0.03	0.01	0.01	-0.03	-0.01
Net Receivables	0.39	0.83	0.51	0.31	0.15	-0.15	0.32	0.35	0.31	-0.42	0.34	0.5	0.65	0.39	-0.14	0.0		-0.01	0.66	0.09	0.32	-0.39	0.27	0.07
Non Current Liabilities Total	-0.08	-0.02	-0.08	-0.13	0.06	0.1	-0.17	-0.1	-0.11	0.09	0.0	0.01	0.08	0.3	-0.12	0.98	-0.01		0.09	-0.09	-0.12	0.14	-0.13	-0.12
Other Current Assets	0.88	0.93	0.95	0.79	0.81	-0.8	0.79	0.79	0.75	-0.42	0.72	0.96	1.0	0.75	0.59	0.2	0.66	0.09		0.75	0.8	-0.87	0.77	0.72
Short Long Term Debt Total	0.92	0.58	0.86	0.91	0.97	-0.94	0.91	0.83	0.78	-0.33	0.83	0.86	0.77	0.58	0.94	0.03	0.09	-0.09	0.75		0.91	-0.83	0.88	0.91
Net Invested Capital	0.99	0.74	0.89	1.0	0.9	-0.87	0.99	0.93	0.9	-0.2	0.85	0.88	0.82	0.7	0.73	0.01	0.32	-0.12	0.8	0.91		-0.86	0.92	0.8
Net Working Capital	-0.92	-0.82	-0.96	-0.86	-0.87	0.94	-0.86	-0.89	-0.92	0.28	-0.74	-0.96	-0.89	-0.8	-0.71	0.01	-0.39	0.14	-0.87	-0.83	-0.86		-0.88	-0.87
Capital Stock	0.93	0.69	0.86	0.92	0.87	-0.89	0.92	0.87	0.85	-0.2	0.77	0.86	0.79	0.77	0.74	-0.03	0.27	-0.13	0.77	0.88	0.92	-0.88		0.92
Current Deferred Revenue	0.84	0.55	0.84	0.8	0.91	-0.96	0.81	0.78	0.76	-0.29	0.71	0.84	0.74	0.68	0.9	-0.01	0.07	-0.12	0.72	0.91	0.8	-0.87	0.92

Click cells to compare fundamentals

Nukkleus Account Relationship Matchups

Nukkleus balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	203.0K	3.8M	16.7M	18.4M	21.1M	22.2M
Other Current Liab	5.0M	4.6M	2.5M	3.6M	4.1M	4.3M
Total Current Liabilities	1.3M	5.2M	4.6M	7.5M	8.6M	9.0M
Total Stockholder Equity	(1.3M)	(1.4M)	12.0M	10.9M	12.5M	13.2M
Net Debt	158.3K	161.0K	1.3M	3.3M	3.8M	4.0M
Retained Earnings	(1.5M)	(1.6M)	(2.5M)	(14.3M)	(12.9M)	(12.3M)
Cash	23.5K	82.8K	355.7K	364.0K	418.6K	439.6K
Cash And Short Term Investments	192.5K	82.9K	355.7K	364.0K	418.6K	439.6K
Common Stock Shares Outstanding	6.3M	257.8M	367.2M	10.1M	9.1M	8.6M
Liabilities And Stockholders Equity	203.0K	3.8M	16.7M	18.4M	21.1M	22.2M
Total Liab	1.5M	5.2M	4.6M	7.5M	8.6M	9.0M
Total Current Assets	203.0K	3.8M	3.0M	3.7M	4.2M	4.5M
Net Tangible Assets	(1.3M)	(1.4M)	(1.6M)	2.8M	3.2M	3.4M
Net Receivables	3.7M	2.7M	35K	966.1K	1.1M	1.0M
Short Term Investments	168.9K	12.0	1.2M	248.2K	285.4K	224.1K
Non Current Liabilities Total	246.2K	247.6K	180.5K	254.9K	229.4K	285.1K
Inventory	(172.8K)	(3.7M)	(2.6M)	2.0M	1.8M	1.9M
Other Current Assets	3.7M	2.6M	3.3M	3.3M	3.8M	4.0M
Short Term Debt	181.8K	243.8K	49.0K	3.7M	4.2M	4.4M
Short Long Term Debt Total	181.8K	243.8K	1.6M	3.7M	4.2M	4.4M
Net Invested Capital	(1.3M)	(1.4M)	12.0M	10.9M	12.5M	13.2M
Net Working Capital	(1.0M)	(1.4M)	(1.6M)	(3.8M)	(3.4M)	(3.2M)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Nukkleus is a strong investment it is important to analyze Nukkleus' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Nukkleus' future performance. For an informed investment choice regarding Nukkleus Stock, refer to the following important reports:

How To Invest In Nukkleus

Details

Is Nukkleus Stock a good investment?

Details

What is Nukkleus' Net Worth?

Details

Largest Application Software Companies

View

Largest Software - Application Companies

View

For more information on how to buy Nukkleus Stock please use our How to buy in Nukkleus Stock guide.

You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nukkleus. If investors know Nukkleus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nukkleus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(19.36)

Revenue Per Share

7.024

Quarterly Revenue Growth

(0.97)

Return On Assets

(1.15)

Return On Equity

(7.42)

The market value of Nukkleus is measured differently than its book value, which is the value of Nukkleus that is recorded on the company's balance sheet. Investors also form their own opinion of Nukkleus' value that differs from its market value or its book value, called intrinsic value, which is Nukkleus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nukkleus' market value can be influenced by many factors that don't directly affect Nukkleus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Nukkleus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nukkleus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nukkleus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Nukkleus Historical Balance Sheet

Nukkleus Inventory

1.91 Million

About Nukkleus Balance Sheet Analysis

Nukkleus Balance Sheet Chart

Total Current Liabilities

Common Stock Shares Outstanding

Nukkleus balance sheet Correlations

Nukkleus Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Nukkleus balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Net Invested Capital	+ 1.0	Total Stockholder Equity
Other Current Assets	+ 1.0	Total Current Assets
Net Invested Capital	+ 0.99	Total Assets
Accounts Payable	+ 0.99	Total Stockholder Equity
Net Invested Capital	+ 0.99	Accounts Payable

Net Working Capital	- 0.96	Total Liab
Current Deferred Revenue	- 0.96	Retained Earnings
Net Working Capital	- 0.96	Total Current Liabilities
Retained Earnings	- 0.95	Net Debt
Short Long Term Debt Total	- 0.94	Retained Earnings
Net Working Capital	- 0.92	Cash And Short Term Investments